Advice

Following a full submission

paliperidone (Invega®) is not recommended for use within NHS Scotland for the treatment of schizophrenia.

Paliperidone has been shown to be superior to placebo in reducing symptoms of schizophrenia. However, there are limited statistical comparative data versus other atypical antipsychotics.

The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Download detailed advice105KB (PDF)

Download

Medicine details

Medicine name:
paliperidone prolonged-release tablets (INVEGA)
SMC ID:
453/08
Indication:
Treatment of schizophrenia
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Central nervous system
Submission type
Full
Status
Not recommended
Date advice published
07 April 2008